ArticleEuropean journal of medical research2025
Prognostic biomarkers in treatment-naïve central retinal vein occlusion with macular edema.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electroretinographical analysis of the effect of cannabidiol (CBD) in eyes of Zucker diabetic fatty rats.Journal of cannabis research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
significance of this studyReduced pulse pressure (PP) reflects impaired systemic perfusion and may exacerbate retinal ischemia in central retinal vein occlusion-induced macular edema (CRVO-ME) by compromising ocular blood flow autoregulation. This hemodynamic dysfunction is hypothesized to worsen clinical outcomes and neovascular risks. PURPOSES: To investigate the associations between potential prognostic biomarkers and clinical outcomes in treatment-naïve CRVO-ME and assess their predictive utilities.
methodsIn this retrospective cohort study conducted from March 2019 to March 2024, we analyzed 101 treatment-naïve CRVO-ME patients stratified by outcomes: favorable (endpoint best-corrected visual acuity [BCVA] ≥ 20/100 without CRVO-induced neovascular glaucoma [CRVO-NVG]) versus unfavorable (endpoint BCVA < 20/100 or CRVO-NVG development). We compared demographic characteristics, baseline blood pressures, ocular features, and systemic biomarkers between groups.
resultsMultivariable logistic regression analysis identified two independent predictors of unfavorable outcomes: suboptimal 1-month post-injection BCVA (odds ratio [OR] = 1.824 per 0.1 log MAR unit increase, 95% confidence intervals [CI] 1.236-2.691, P = 0.002) and diminished PP (OR = 1.147 per mmHg decrease, 95% CI 1.028-1.279, P = 0.015). Receiver operating characteristic analysis demonstrated strong predictive accuracy for both parameters (1-month post-injection BCVA: area under the receiver operating characteristic curve [AUROC] = 0.843, cutoff 0.85 logarithm of the minimum angle of resolution [log MAR], P = 0.000; PP: AUROC = 0.812, cutoff 57 mmHg, P = 0.000). In the ischemic CRVO-ME subgroup (n = 27), the optical coherence tomography (OCT)-defined "over-response to the first intravitreal injection (ORIVI)" emerged as the sole significant predictor of CRVO-NVG development (OR = 15.167, 95% CI 1.509-152.464, P = 0.026).
conclusionThis study establishes baseline PP < 57 mmHg and suboptimal 1-month post-injection BCVA > 0.85 log MAR as key prognostic indicators in CRVO-ME, while identifying the ORIVI sign as a specific predictor of CRVO-NVG in ischemic cases. These findings introduce easily obtainable systemic parameter (PP) for risk assessment, define 1-month visual response as key treatment evaluation point, propose ORIVI sign as an imaging biomarker for ischemic CRVO complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.